TrialHaematologica2024
Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
Johannes Duell et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this papertrialcites it